WASHINGTON -- The Obama administration is trying to allow states greater flexibility to change their Medicaid programs without asking the federal government for special waivers, a top health official said here Thursday.
For example, the Centers for Medicare and Medicaid Services (CMS) has tried to ease regulations in recent months -- beginning last August -- to allow states to create integrated delivery models for Medicaid without such waivers, Cindy Mann, JD, said at a meeting of the Medicaid and CHIP Payment and Access Commission (MACPAC).
More recently, CMS allowed states to increase patient cost-sharing for using nonpreferred drugs or making unnecessary emergency department visits, said Mann, who is director of Medicaid and the Children's Health Insurance Program (CHIP) at CMS.
Read the full story here: http://bit.ly/111HUud
Source: MedPageToday.com
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Antismoking groups sued the US government over the long-awaited menthol cigarette ban; the fill rate for Adderall and Vyvanse dropped more than 10% in 2 years despite soaring demand; the Biden administration has responded to offers from the manufacturers of drugs selected for Medicare pricing negotiations.
Read More